Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Prostate Cancer

  Free Subscription


Articles published in Br J Cancer

Retrieve available abstracts of 93 articles:
HTML format



Single Articles


    May 2021
  1. FILON M, Gawdzik J, Truong A, Allen G, et al
    Tandem histone methyltransferase upregulation defines a unique aggressive prostate cancer phenotype.
    Br J Cancer. 2021 May 11. pii: 10.1038/s41416-021-01398.
    PubMed     Abstract available


    April 2021
  2. EMOND JP, Lacombe L, Caron P, Turcotte V, et al
    Urinary oestrogen steroidome as an indicator of the risk of localised prostate cancer progression.
    Br J Cancer. 2021 Apr 7. pii: 10.1038/s41416-021-01376.
    PubMed     Abstract available


    January 2021
  3. ZHAO Z, Zhao S, Luo L, Xiang Q, et al
    Correction: miR-199b-5p-DDR1-ERK signalling axis suppresses prostate cancer metastasis via inhibiting epithelial-mesenchymal transition.
    Br J Cancer. 2021 Jan 13. pii: 10.1038/s41416-020-01258.
    PubMed    


    December 2020
  4. NIKHIL K, Haymour HS, Kamra M, Shah K, et al
    Phosphorylation-dependent regulation of SPOP by LIMK2 promotes castration-resistant prostate cancer.
    Br J Cancer. 2020 Dec 14. pii: 10.1038/s41416-020-01197.
    PubMed     Abstract available


  5. LIU S, Shen M, Hsu EC, Zhang CA, et al
    Discovery of PTN as a serum-based biomarker of pro-metastatic prostate cancer.
    Br J Cancer. 2020 Dec 8. pii: 10.1038/s41416-020-01200.
    PubMed     Abstract available


  6. AMERATUNGA M, Brana I, Bono P, Postel-Vinay S, et al
    First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours.
    Br J Cancer. 2020;123:1730-1736.
    PubMed     Abstract available


    November 2020
  7. ZHAO Z, Zhao S, Luo L, Xiang Q, et al
    miR-199b-5p-DDR1-ERK signalling axis suppresses prostate cancer metastasis via inhibiting epithelial-mesenchymal transition.
    Br J Cancer. 2020 Nov 26. pii: 10.1038/s41416-020-01187.
    PubMed     Abstract available


    October 2020
  8. LOZANO R, Castro E, Aragon IM, Cendon Y, et al
    Genetic aberrations in DNA repair pathways: a cornerstone of precision oncology in prostate cancer.
    Br J Cancer. 2020 Oct 27. pii: 10.1038/s41416-020-01114.
    PubMed     Abstract available


  9. LI T, Liu N, Gao Y, Quan Z, et al
    Long noncoding RNA HOTAIR regulates the invasion and metastasis of prostate cancer by targeting hepaCAM.
    Br J Cancer. 2020 Oct 7. pii: 10.1038/s41416-020-01091.
    PubMed     Abstract available


    September 2020
  10. MOUT L, Moll JM, Chen M, de Morree ES, et al
    Androgen receptor signalling impairs docetaxel efficacy in castration-resistant prostate cancer.
    Br J Cancer. 2020 Sep 29. pii: 10.1038/s41416-020-01105.
    PubMed     Abstract available


  11. WANG LP, Chen TY, Kang CK, Huang HP, et al
    BCAS2, a protein enriched in advanced prostate cancer, interacts with NBS1 to enhance DNA double-strand break repair.
    Br J Cancer. 2020 Sep 23. pii: 10.1038/s41416-020-01086.
    PubMed     Abstract available


  12. PEREZ-CORNAGO A, Fensom GK, Andrews C, Watts EL, et al
    Examination of potential novel biochemical factors in relation to prostate cancer incidence and mortality in UK Biobank.
    Br J Cancer. 2020 Sep 23. pii: 10.1038/s41416-020-01081.
    PubMed     Abstract available


  13. NASTALY P, Stoupiec S, Popeda M, Smentoch J, et al
    EGFR as a stable marker of prostate cancer dissemination to bones.
    Br J Cancer. 2020 Sep 9. pii: 10.1038/s41416-020-01052.
    PubMed     Abstract available


    August 2020
  14. HAESE A, Tin AL, Carlsson SV, Sjoberg DD, et al
    A pre-specified model based on four kallikrein markers in blood improves predictions of adverse pathology and biochemical recurrence after radical prostatectomy.
    Br J Cancer. 2020;123:604-609.
    PubMed     Abstract available


    July 2020
  15. CONTEDUCA V, Wetterskog D, Scarpi E, Romanel A, et al
    Plasma tumour DNA as an early indicator of treatment response in metastatic castration-resistant prostate cancer.
    Br J Cancer. 2020 Jul 16. pii: 10.1038/s41416-020-0969.
    PubMed     Abstract available


  16. NOBLE SM, Garfield K, Lane JA, Metcalfe C, et al
    The ProtecT randomised trial cost-effectiveness analysis comparing active monitoring, surgery, or radiotherapy for prostate cancer.
    Br J Cancer. 2020 Jul 16. pii: 10.1038/s41416-020-0978.
    PubMed     Abstract available


  17. PHILIPPOU Y, Sjoberg HT, Murphy E, Alyacoubi S, et al
    Impacts of combining anti-PD-L1 immunotherapy and radiotherapy on the tumour immune microenvironment in a murine prostate cancer model.
    Br J Cancer. 2020 Jul 9. pii: 10.1038/s41416-020-0956.
    PubMed     Abstract available


    June 2020
  18. LI L, Hobson L, Perry L, Clark B, et al
    Targeting the ERG oncogene with splice-switching oligonucleotides as a novel therapeutic strategy in prostate cancer.
    Br J Cancer. 2020 Jun 25. pii: 10.1038/s41416-020-0951.
    PubMed     Abstract available


    May 2020
  19. FENG X, Song M, Preston MA, Ma W, et al
    The association of diabetes with risk of prostate cancer defined by clinical and molecular features.
    Br J Cancer. 2020 May 29. pii: 10.1038/s41416-020-0910.
    PubMed     Abstract available


  20. HUR J, Giovannucci E
    Racial differences in prostate cancer: does timing of puberty play a role?
    Br J Cancer. 2020 May 22. pii: 10.1038/s41416-020-0897.
    PubMed     Abstract available


  21. BUTLER EN, Kelly SP, Coupland VH, Rosenberg PS, et al
    Fatal prostate cancer incidence trends in the United States and England by race, stage, and treatment.
    Br J Cancer. 2020 May 20. pii: 10.1038/s41416-020-0859.
    PubMed     Abstract available


    March 2020
  22. LUCA BA, Moulton V, Ellis C, Edwards DR, et al
    A novel stratification framework for predicting outcome in patients with prostate cancer.
    Br J Cancer. 2020 Mar 20. pii: 10.1038/s41416-020-0799.
    PubMed     Abstract available


    February 2020
  23. LEVESQUE E, Labriet A, Hovington H, Allain EP, et al
    Alternative promoters control UGT2B17-dependent androgen catabolism in prostate cancer and its influence on progression.
    Br J Cancer. 2020 Feb 12. pii: 10.1038/s41416-020-0749.
    PubMed     Abstract available


    January 2020
  24. EL-KENAWI A, Gatenbee C, Robertson-Tessi M, Bravo R, et al
    Correction: Acidity promotes tumour progression by altering macrophage phenotype in prostate cancer.
    Br J Cancer. 2020 Jan 14. pii: 10.1038/s41416-019-0710.
    PubMed     Abstract available


    December 2019
  25. RUSHWORTH LK, Hewit K, Munnings-Tomes S, Somani S, et al
    Repurposing screen identifies mebendazole as a clinical candidate to synergise with docetaxel for prostate cancer treatment.
    Br J Cancer. 2019 Dec 17. pii: 10.1038/s41416-019-0681.
    PubMed     Abstract available


    November 2019
  26. ROUYER M, Oudard S, Joly F, Fizazi K, et al
    Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort.
    Br J Cancer. 2019 Nov 13. pii: 10.1038/s41416-019-0611.
    PubMed     Abstract available


  27. NOBLE AR, Hogg K, Suman R, Berney DM, et al
    Phospholipase D2 in prostate cancer: protein expression changes with Gleason score.
    Br J Cancer. 2019 Nov 1. pii: 10.1038/s41416-019-0610.
    PubMed     Abstract available


    October 2019
  28. LIMA AR, Pinto J, Azevedo AI, Barros-Silva D, et al
    Identification of a biomarker panel for improvement of prostate cancer diagnosis by volatile metabolic profiling of urine.
    Br J Cancer. 2019 Oct 7. pii: 10.1038/s41416-019-0585.
    PubMed     Abstract available


    September 2019
  29. ZHAO J, Giri A, Zhu X, Shrubsole MJ, et al
    Calcium: magnesium intake ratio and colorectal carcinogenesis, results from the prostate, lung, colorectal, and ovarian cancer screening trial.
    Br J Cancer. 2019 Sep 23. pii: 10.1038/s41416-019-0579.
    PubMed     Abstract available


  30. THURTLE DR, Jenkins V, Pharoah PD, Gnanapragasam VJ, et al
    Understanding of prognosis in non-metastatic prostate cancer: a randomised comparative study of clinician estimates measured against the PREDICT prostate prognostic model.
    Br J Cancer. 2019 Sep 16. pii: 10.1038/s41416-019-0569.
    PubMed     Abstract available


    August 2019
  31. EL-KENAWI A, Gatenbee C, Robertson-Tessi M, Bravo R, et al
    Acidity promotes tumour progression by altering macrophage phenotype in prostate cancer.
    Br J Cancer. 2019 Aug 16. pii: 10.1038/s41416-019-0542.
    PubMed     Abstract available


  32. QUINN DI, Stricker PD, Kench JG, Grogan J, et al
    p53 nuclear accumulation as an early indicator of lethal prostate cancer.
    Br J Cancer. 2019 Aug 14. pii: 10.1038/s41416-019-0549.
    PubMed     Abstract available


    June 2019
  33. JATHAL MK, Steele TM, Siddiqui S, Mooso BA, et al
    Dacomitinib, but not lapatinib, suppressed progression in castration-resistant prostate cancer models by preventing HER2 increase.
    Br J Cancer. 2019 Jun 18. pii: 10.1038/s41416-019-0496.
    PubMed     Abstract available


    May 2019
  34. FRANTZI M, Gomez Gomez E, Blanca Pedregosa A, Valero Rosa J, et al
    CE-MS-based urinary biomarkers to distinguish non-significant from significant prostate cancer.
    Br J Cancer. 2019 May 16. pii: 10.1038/s41416-019-0472.
    PubMed     Abstract available


  35. MOUSTSEN IR, Larsen SB, Duun-Henriksen AK, Tjonneland A, et al
    Risk of cardiovascular events in men treated for prostate cancer compared with prostate cancer-free men.
    Br J Cancer. 2019 May 8. pii: 10.1038/s41416-019-0468.
    PubMed     Abstract available


    April 2019
  36. ZIETMAN AL
    Can proton therapy be considered a standard of care in oncology? Lessons from the United States.
    Br J Cancer. 2019;120:775-776.
    PubMed    


    March 2019
  37. MIJUSKOVIC M, Saunders EJ, Leongamornlert DA, Wakerell S, et al
    Correction: Rare germline variants in DNA repair genes and the angiogenesis pathway predispose prostate cancer patients to develop metastatic disease.
    Br J Cancer. 2019 Mar 6. pii: 10.1038/s41416-019-0419.
    PubMed     Abstract available


    February 2019
  38. DUTTO L, Ahmad A, Urbanova K, Wagner C, et al
    Correction: Development and validation of a novel risk score for the detection of insignificant prostate cancer in unscreened patient cohorts.
    Br J Cancer. 2019 Feb 27. pii: 10.1038/s41416-019-0408.
    PubMed     Abstract available


    January 2019
  39. GREGG JR, Zheng J, Lopez DS, Reichard C, et al
    Diet quality and Gleason grade progression among localised prostate cancer patients on active surveillance.
    Br J Cancer. 2019 Jan 25. pii: 10.1038/s41416-019-0380.
    PubMed     Abstract available


    November 2018
  40. DUTTO L, Ahmad A, Urbanova K, Wagner C, et al
    Development and validation of a novel risk score for the detection of insignificant prostate cancer in unscreened patient cohorts.
    Br J Cancer. 2018 Nov 27. pii: 10.1038/s41416-018-0316.
    PubMed     Abstract available


  41. SCHMIDT L, Moller M, Haldrup C, Strand SH, et al
    Exploring the transcriptome of hormone-naive multifocal prostate cancer and matched lymph node metastases.
    Br J Cancer. 2018 Nov 19. pii: 10.1038/s41416-018-0321.
    PubMed     Abstract available


  42. PREISSER F, Mazzone E, Nazzani S, Marchioni M, et al
    North American population-based validation of the National Comprehensive Cancer Network Practice Guideline Recommendations for locoregional lymph node and bone imaging in prostate cancer patients.
    Br J Cancer. 2018 Nov 14. pii: 10.1038/s41416-018-0323.
    PubMed     Abstract available


    October 2018
  43. AL-SAFFAR NMS, Troy H, Wong Te Fong AC, Paravati R, et al
    Metabolic biomarkers of response to the AKT inhibitor MK-2206 in pre-clinical models of human colorectal and prostate carcinoma.
    Br J Cancer. 2018 Oct 31. pii: 10.1038/s41416-018-0242.
    PubMed     Abstract available


  44. TEO MY, Scher HI
    Lessons from the SWITCH trial: changing glucocorticoids in the management of metastatic castration-resistant prostate cancer (mCRPC).
    Br J Cancer. 2018 Oct 22. pii: 10.1038/s41416-018-0239.
    PubMed     Abstract available


  45. PELLACANI D, Droop AP, Frame FM, Simms MS, et al
    Phenotype-independent DNA methylation changes in prostate cancer.
    Br J Cancer. 2018 Oct 15. pii: 10.1038/s41416-018-0236.
    PubMed     Abstract available


    August 2018
  46. ROMERO-LAORDEN N, Lozano R, Jayaram A, Lopez-Campos F, et al
    Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH study).
    Br J Cancer. 2018 Aug 21. pii: 10.1038/s41416-018-0123.
    PubMed     Abstract available


    July 2018
  47. DAL MASO L, Zucchetto A, Stocco C, Serraino D, et al
    Comment on 'Anthropometric measurements and survival after prostate cancer diagnosis'.
    Br J Cancer. 2018 Jul 31. pii: 10.1038/s41416-018-0161.
    PubMed    


  48. FARRIS MS, Courneya KS, Kopciuk KA, McGregor SE, et al
    Reply to 'Comment on 'Anthropometric measurements and survival after prostate cancer diagnosis".
    Br J Cancer. 2018 Jul 31. pii: 10.1038/s41416-018-0213.
    PubMed    


  49. KALLIO HML, Hieta R, Latonen L, Brofeldt A, et al
    Constitutively active androgen receptor splice variants AR-V3, AR-V7 and AR-V9 are co-expressed in castration-resistant prostate cancer metastases.
    Br J Cancer. 2018 Jul 10. pii: 10.1038/s41416-018-0172.
    PubMed     Abstract available


    June 2018
  50. HIRATA H, Hinoda Y, Shahryari V, Deng G, et al
    Correction: Genistein downregulates onco-miR-1260b and upregulates sFRP1 and Smad4 via demethylation and histone modification in prostate cancer cells.
    Br J Cancer. 2018 Jun 22. pii: 10.1038/s41416-018-0146.
    PubMed     Abstract available


  51. MIJUSKOVIC M, Saunders EJ, Leongamornlert DA, Wakerell S, et al
    Rare germline variants in DNA repair genes and the angiogenesis pathway predispose prostate cancer patients to develop metastatic disease.
    Br J Cancer. 2018 Jun 19. pii: 10.1038/s41416-018-0141.
    PubMed     Abstract available


  52. ZHENG R, Du M, Zhang B, Xin J, et al
    Body mass index (BMI) trajectories and risk of colorectal cancer in the PLCO cohort.
    Br J Cancer. 2018 Jun 6. pii: 10.1038/s41416-018-0121.
    PubMed     Abstract available


    May 2018
  53. GAO F, Alwhaibi A, Artham S, Verma A, et al
    Endothelial Akt1 loss promotes prostate cancer metastasis via beta-catenin-regulated tight-junction protein turnover.
    Br J Cancer. 2018 May 14. pii: 10.1038/s41416-018-0110.
    PubMed     Abstract available


    March 2018
  54. WALLIS CJD, Morton G, Herschorn S, Kodama RT, et al
    The effect of selection and referral biases for the treatment of localised prostate cancer with surgery or radiation.
    Br J Cancer. 2018 Mar 29. pii: 10.1038/s41416-018-0071.
    PubMed     Abstract available


  55. MURTOLA TJ, Vihervuori VJ, Lahtela J, Talala K, et al
    Fasting blood glucose, glycaemic control and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer.
    Br J Cancer. 2018 Mar 22. pii: 10.1038/s41416-018-0055.
    PubMed     Abstract available


  56. MIKROPOULOS C, Hutten Selkirk CG, Saya S, Bancroft E, et al
    Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition.
    Br J Cancer. 2018 Mar 6. pii: bjc201811. doi: 10.1038/bjc.2018.
    PubMed     Abstract available


  57. MCCLURG UL, Nabbi A, Ricordel C, Korolchuk S, et al
    Human ex vivo prostate tissue model system identifies ING3 as an oncoprotein.
    Br J Cancer. 2018;118:713-726.
    PubMed     Abstract available


    February 2018
  58. BRAADLAND PR, Giskeodegard G, Sandsmark E, Bertilsson H, et al
    Ex vivo metabolic fingerprinting identifies biomarkers predictive of prostate cancer recurrence following radical prostatectomy.
    Br J Cancer. 2018 Feb 20. pii: bjc2017470. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


  59. GANJU A, Chauhan SC, Hafeez BB, Doxtater K, et al
    Protein kinase D1 regulates subcellular localisation and metastatic function of metastasis-associated protein 1.
    Br J Cancer. 2018;118:587-599.
    PubMed     Abstract available


  60. NOSSITER J, Sujenthiran A, Charman SC, Cathcart PJ, et al
    Robot-assisted radical prostatectomy vs laparoscopic and open retropubic radical prostatectomy: functional outcomes 18 months after diagnosis from a national cohort study in England.
    Br J Cancer. 2018;118:489-494.
    PubMed     Abstract available


  61. LOPHATANANON A, Stewart-Brown S, Kote-Jarai Z, Al Olama AA, et al
    Height, selected genetic markers and prostate cancer risk: results from the PRACTICAL consortium.
    Br J Cancer. 2018 Feb 13. pii: bjc20186. doi: 10.1038/bjc.2018.
    PubMed     Abstract available


  62. SAUNDERS EJ, Dadaev T, Leongamornlert DA, Al Olama AA, et al
    Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array.
    Br J Cancer. 2018 Feb 13. pii: bjc2017468. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


    January 2018
  63. LEE GT, Kwon SJ, Kim J, Kwon YS, et al
    WNT5A induces castration-resistant prostate cancer via CCL2 and tumour-infiltrating macrophages.
    Br J Cancer. 2018 Jan 30. pii: bjc2017451. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


  64. QU S, Ci X, Xue H, Dong X, et al
    Treatment with docetaxel in combination with Aneustat leads to potent inhibition of metastasis in a patient-derived xenograft model of advanced prostate cancer.
    Br J Cancer. 2018 Jan 30. pii: bjc2017474. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


  65. MIKROPOULOS C, Selkirk CGH, Saya S, Bancroft E, et al
    Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition.
    Br J Cancer. 2018 Jan 4. pii: bjc2017429. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


    December 2017
  66. FARRIS MS, Courneya KS, Kopciuk KA, McGregor SE, et al
    Anthropometric measurements and survival after a prostate cancer diagnosis.
    Br J Cancer. 2017 Dec 12. pii: bjc2017440. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


    November 2017
  67. KAWAKITA D, Lee YA, Gren LH, Buys SS, et al
    The impact of folate intake on the risk of head and neck cancer in the prostate, lung, colorectal, and ovarian cancer screening trial (PLCO) cohort.
    Br J Cancer. 2017 Nov 21. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


  68. BRAVO I
    Comment on 'Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study'.
    Br J Cancer. 2017 Nov 16. doi: 10.1038/bjc.2017.
    PubMed    


  69. TRIGGIANI L, Mazzola R, Magrini SM, Alongi F, et al
    Reply to 'Comment on 'Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study''.
    Br J Cancer. 2017 Nov 16. doi: 10.1038/bjc.2017.
    PubMed    


  70. NOBLE AR, Maitland NJ, Berney DM, Rumsby MG, et al
    Phospholipase D inhibitors reduce human prostate cancer cell proliferation and colony formation.
    Br J Cancer. 2017 Nov 14. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


  71. LI P, Chen J, Kashiwagi E, Mizushima T, et al
    The interaction between androgen receptor and semenogelin I: a synthetic LxxLL peptide antagonist inhibits the growth of prostate cancer cells.
    Br J Cancer. 2017 Nov 14. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


  72. HU J, Tian J, Zhu S, Sun L, et al
    Sox5 contributes to prostate cancer metastasis and is a master regulator of TGF-beta-induced epithelial mesenchymal transition through controlling Twist1 expression.
    Br J Cancer. 2017 Nov 9. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


    October 2017
  73. HAQUE R, UlcickasYood M, Xu X, Cassidy-Bushrow AE, et al
    Cardiovascular disease risk and androgen deprivation therapy in patients with localised prostate cancer: a prospective cohort study.
    Br J Cancer. 2017;117:1233-1240.
    PubMed     Abstract available


  74. LIU W, Wang X, Liu Z, Wang Y, et al
    SGK1 inhibition induces autophagy-dependent apoptosis via the mTOR-Foxo3a pathway.
    Br J Cancer. 2017;117:1139-1153.
    PubMed     Abstract available


  75. BRAADLAND PR, Giskeodegard G, Sandsmark E, Bertilsson H, et al
    Ex vivo metabolic fingerprinting identifies biomarkers predictive of prostate cancer recurrence following radical prostatectomy.
    Br J Cancer. 2017 Oct 3. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


  76. ALEKSIC T, Verrill C, Bryant RJ, Han C, et al
    IGF-1R associates with adverse outcomes after radical radiotherapy for prostate cancer.
    Br J Cancer. 2017 Oct 3. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


    September 2017
  77. PEREZ-CORNAGO A, Key TJ, Allen NE, Fensom GK, et al
    Prospective investigation of risk factors for prostate cancer in the UK Biobank cohort study.
    Br J Cancer. 2017 Sep 14. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


  78. DEMARK-WAHNEFRIED W, Rais-Bahrami S, Desmond RA, Gordetsky JB, et al
    Presurgical weight loss affects tumour traits and circulating biomarkers in men with prostate cancer.
    Br J Cancer. 2017 Sep 7. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


    August 2017
  79. CALLAHAN CL, Schwartz K, Ruterbusch JJ, Shuch B, et al
    Leukocyte telomere length and renal cell carcinoma survival in two studies.
    Br J Cancer. 2017;117:752-755.
    PubMed     Abstract available


  80. PIROVANO G, Ashton TM, Herbert KJ, Bryant RJ, et al
    TOPK modulates tumour-specific radiosensitivity and correlates with recurrence after prostate radiotherapy.
    Br J Cancer. 2017;117:503-512.
    PubMed     Abstract available


  81. LOPHATANANON A, Stewart-Brown S, Kote-Jarai Z, Olama AAA, et al
    Height, selected genetic markers and prostate cancer risk: results from the PRACTICAL consortium.
    Br J Cancer. 2017 Aug 1. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


    July 2017
  82. CYLL K, Ersvaer E, Vlatkovic L, Pradhan M, et al
    Tumour heterogeneity poses a significant challenge to cancer biomarker research.
    Br J Cancer. 2017;117:367-375.
    PubMed     Abstract available


  83. DAI Y, Ren D, Yang Q, Cui Y, et al
    The TGF-beta signalling negative regulator PICK1 represses prostate cancer metastasis to bone.
    Br J Cancer. 2017 Jul 11. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


    June 2017
  84. PAL D, Suman S, Kolluru V, Sears S, et al
    Inhibition of autophagy prevents cadmium-induced prostate carcinogenesis.
    Br J Cancer. 2017;117:56-64.
    PubMed     Abstract available


  85. MARTIKAINEN M, Ruotsalainen J, Tuomela J, Harkonen P, et al
    Oncolytic alphavirus SFV-VA7 efficiently eradicates subcutaneous and orthotopic human prostate tumours in mice.
    Br J Cancer. 2017;117:51-55.
    PubMed     Abstract available


  86. SAMARENDRA H, Jones K, Petrinic T, Silva MA, et al
    A meta-analysis of CXCL12 expression for cancer prognosis.
    Br J Cancer. 2017;117:124-135.
    PubMed     Abstract available


  87. GOTO Y, Kurozumi A, Arai T, Nohata N, et al
    Impact of novel miR-145-3p regulatory networks on survival in patients with castration-resistant prostate cancer.
    Br J Cancer. 2017 Jun 22. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


    May 2017
  88. BARRY KH, Moore LE, Sampson JN, Koutros S, et al
    Prospective study of DNA methylation at chromosome 8q24 in peripheral blood and prostate cancer risk.
    Br J Cancer. 2017 May 2. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


    April 2017
  89. TRIGGIANI L, Alongi F, Buglione M, Detti B, et al
    Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study.
    Br J Cancer. 2017 Apr 27. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


  90. SIMMONS LAM, Kanthabalan A, Arya M, Briggs T, et al
    The PICTURE study: diagnostic accuracy of multiparametric MRI in men requiring a repeat prostate biopsy.
    Br J Cancer. 2017;116:1159-1165.
    PubMed     Abstract available


  91. JANSSEN A, Verkleij CP, van der Vlist A, Mathijssen RH, et al
    Towards better dose individualisation: metabolic phenotyping to predict cabazitaxel pharmacokinetics in men with prostate cancer.
    Br J Cancer. 2017 Apr 11. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


    March 2017
  92. LEE GT, Han CS, Kwon YS, Patel R, et al
    Intracrine androgen biosynthesis in renal cell carcinoma.
    Br J Cancer. 2017;116:937-943.
    PubMed     Abstract available


  93. MITTAL K, Donthamsetty S, Kaur R, Yang C, et al
    Multinucleated polyploidy drives resistance to Docetaxel chemotherapy in prostate cancer.
    Br J Cancer. 2017 Mar 23. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: